Designed multiple ligands. An emerging drug discovery paradigm

Journal of Medicinal Chemistry

Volumn 48, Issue 21, 2005, Pages 6523-6543

  Morphy, Richard ^a   Rankovic, Zoran ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 6 HYDROXY 4,5,7 TRIMETHYL 2 (4 SULFAMOYLBENZYLAMINO)BENZOTHIAZOLE; 6 HYDROXY 5,7 DIMETHYL 2 METHYLAMINO 4 (3 PYRIDYLMETHYL)BENZOTHIAZOLE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; AGMATINE; AMITRIPTYLINE; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CELECOXIB; CETIRIZINE; CMI 977; CYCLOOXYGENASE 2 INHIBITOR; DARBUFELONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DULOXETINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENTANYL DERIVATIVE; FLUOXETINE; IMATINIB; MILNACIPRAN; N (2 MERCAPTOMETHYL 3 PHENYLPROPIONYL) BETA ALANINE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PINDOLOL; PRIFELONE; QUETIAPINE; RISPERIDONE; RUPATADINE; SB 649915; SIMVASTATIN; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CONFORMATION; DRUG CONJUGATION; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IC 50; PARKINSONISM; REVIEW; STRUCTURE ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; LIGANDS; METABOLIC DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE H1; SEROTONIN UPTAKE INHIBITORS;

EID: 27144449695     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058225d     Document Type: Review

References (108)

1. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discovery 2004, 3, 353-359.
2. Law, M. R.; Wald, J.; Morris, J. K.; Jordan, R. E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br. Med. J. 2003, 326, 1427-1431.
3. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discovery 2005, 4, 1-7.
4. Takano, H.; Sawada, K.; Sato, N.; Natoya, A.; Tarumi, T.; Hirayama, S.; Koizumi, K.; Takahashi, T. A.; Sekiguchi, S.; Koike, T. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 1996, 21, 473-478.
5. Larder, B. A.; Kemp, S. D.; Harrigan, P. R. Potential mechanism for sustained antiretroviral effiacy of AZT-3TC combination therapy. Science 1995, 269, 696-699.
6. Eisen, S. A.; Miller, D. K.; Woodward, R. S.; Spitznagel, E.; Przybeck, T. R. The effect of prescribed daily dose frequency on patient medical compliance. Arch. Intern. Med. 1990, 150, 1881-1884.
7. Skolnik, N. S.; Beck, J. D.; Clark, M. Combination antihypertensive drugs: Recommendations for use. Am. Fam. Physician 2000, 61, 3049-3056.
8. Glass, G. Cardiovascular combinations. Nat. Rev. Drug Discovery 2004, 3, 731-732.
9. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
10. Frishman, W. H.; Zuckerman, A. L. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovas. Ther. 2004, 2, 675-681.
11. Flores, N. A. Ezetimibe + simvastatin (Merck/Schering-Plough). Curr. Opin. Invest. Drugs 2004, 5, 984-992.
12. Edwards, I. R.; Aronson, J. K. Adverse drug reactions: Definitions, diagnosis and management. Lancet 2000, 356, 1255-1259.
13. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry 1997, 54, 567-572.
14. Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents J. Med. Chem. 2004, 47, 143-157.
15. Jones, H. M.; Pilowsky, L. S. New targets for antipsychotics. Expert Rev. Neurother. 2002, 2, 61-68.
16. Stahl, S. M.; Entsuah, R.; Rudolph, R. L. Comparative Efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biol. Psychiatry 2002, 202, 1166-1174.
17. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38, 645-659.
18. Buijsman, R. C.; Basten, J. E.; van Dinther, T. G.; van der Marel, G. A.; van Boeckel, C. A.; van Boom, J. H. Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action. Bioorg. Med. Chem. Lett. 1999, 9, 2013-2018.
19. Jacobson, K. A.; Xie, R.; Young, L.; Chang, L.; Liang, B. T. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. J. Biol. Chem. 2000, 275, 30272-30279.
20. Portoghese, P. S. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 2001, 44, 2259-2269.
21. Daniels, D. J.; Kulkarni, A.; Xie, Z.; Bhushan, R. G.; Portoghese, P. S. A bivalent ligand (KDAN-18) containing δ-antagonist and κ-agonist pharmacophores bridges δ2 and κ1 opioid receptor phenotypes. J. Med. Chem. 2005, 48, 1713-1716.
22. Di Napoli, M.; Papa, F. NCX-4016 NicOX. Curr. Opin. Invest. Drugs 2003, 4, 1126-1139.
23. Lolli, M. L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Coruzzi, G.; Manarini, S.; Fruttero, R.; Gasco, A. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem. 2001, 44, 3463-3468.
24. 2 and gastrin receptor antagonists. Bioorg. Med. Chem. Lett. 1996, 6, 1427-1430.
25. 2-imidazoline receptors: synthesis and pharmacological screening. Bioorg. Med. Chem. 2002, 10, 1009-1018.
26. 2-imidazoline binding sites. Bioorg. Med. Chem. Lett. 2004, 14, 491-493.
27. 2 receptors. Bioorg. Med. Chem. Lett. 1996, 6, 951-956.
28. Yamamoto, M.; Ikeda, S.; Kondo, H.; Inoue, S. Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin. Bioorg. Med. Chem. Lett. 2002, 12, 375-378.
29. Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T.; Kogen, H. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. 2003, 11, 4389-4415.
30. 1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg. Med. Chem. Lett. 2002, 12, 261-264.
31. 1A and 5-HT re-uptake ligands. Bioorg. Med. Chem. Lett. 1999, 9, 3243-3248.
32. 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett. 2001, 11, 319-321.
33. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 46, 550-557.
34. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discovery 2004, 12, 1001-1010.
35. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N.; Traxler, P. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 1221-1226.
36. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 1997, 7, 187-192.
37. Boschelli, D.; Wang, Y.; Johnson, S.; Wu, B.; Ye, F.; Sosa, A.; Golas, J.; Boschelli, F. 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem. 2004, 47, 1599-1601.
38. 2-adrenoreceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues. J. Med. Chem. 1998, 41, 4915-4917.
39. Atkinson, P.; Bromidge, S.; Duxon, M.; Laramie, M.; Gaster, L.; Hadley, M.; Hammond, B.; Johnson, C.; Middlemiss, D.; North, S.; Price, G.; Rami, H.; Riley, J.; Scott, C.; Shaw, T.; Starr, K.; Stemp, G.; Thewlis, K.; Thomas, D.; Thompson, M.; Vong, A.; Watson, J. 3,4-Dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity. Bioorg. Med. Chem. Lett. 2005, 15, 737-741.
40. 3 affinity. Bioorg. Med. Chem. Lett. 2002, 12, 2355-2358.
41. The medicinal chemistry journals covered were Bioorg. Med. Chem. Lett., Bioorg. Med. Chem., J. Med. Chem., and Eur. J. Med. Chem.
42. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 1996, 219, 123-126.
43. Perez, M.; Pauwelsb, P.; Pallard-Sigogneaua, I.; Fourriera, C.; Chopinc, P.; Palmierb, C.; Colovrayd, V.; Halazy, S. Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 3423-3428.
44. Mewshaw, R.; Meagher, K.; Zhou, P.; Zhou, D.; Shi, X.; Scerni, R.; Smith, D.; Schechter, L.; Andree, T. Studies toward the discovery of the next generation of antidepressants. Part 2: Incorporating a 5-HT1A antagonist component into a class of serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 307-310.
45. Mewshaw, R.; Zhou, D.; Zhou, P.; Shi, X.; Hornby, G.; Spangler, T.; Scerni, R.; Smith, D.; Schechter, L.; Andree, T. Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines. J. Med. Chem. 2004, 47, 3823-3842.
46. Timms, G.; Boot, J.; Broadmore, R.; Carney, S.; Cooper, J.; Findlay, J.; Gilmore, J.; Mitchell, S.; Moore, N.; Pullar, I.; Sanger, G.; Tomlinson, R.; Tree, B.; Wedley, S. SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis. Bioorg. Med. Chem. Lett. 2004, 14, 2469-2472.
47. Torrado, A.; Lamas, C.; Agejas, J.; Jiménez, A.; Dxc6ìaza, N.; Gilmore, J.; Boot, J.; Findlay, J.; Hayhurst, L.; Wallace, L.; Broadmore, R.; Tomlinson, R. Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives. Bioorg. Med. Chem. 2004, 12, 5277-5295.
48. Feuerstein, T. H.; Hertting, G. Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: Evidence for facilitatory 5-HT receptors within the CNS. Naunyn-Schmiedeberg's Arch. Pharmacol. 1986, 333, 191-197.
49. 2-antagonistic activities. J. Med. Chem. 1997, 40, 1049-1062.
50. Meyer, M.; Hancock, A.; Tietje, K.; Sippy, K.; Giardina, W.; Kerwin, J. Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining alpha-2 antagonism with 5-HT uptake inhibition. Bioorg. Med. Chem. Lett. 1995, 5, 2287-2292.
51. Bymaster, F.; Beedle, E.; Findlay, J.; Gallagher, P.; Krushinski, J.; Mitchell, S.; Robertson, D.; Thompson, D.; Wallace, L.; Wong, D. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg. Med. Chem. Lett. 2003, 13, 4477-4480.
52. Axford, L.; Boot, J.; Hotten, T.; Keenan, M.; Martin, F.; Milutinovic, S.; Moore, N.; O'Neill, M.; Pullar, I.; Tupper, D.; Van Belle, K.; Vivien, V. Bicyclo[2.2.1]heptanes as novel triple reuptake inhibitors for the treatment of depression. Bioorg. Med. Chem. Lett. 2003, 13, 3277-3280.
53. 2 activity was risperidone: Janssen, P. A.; Niemegeers, C. J.; Awouters, F.; Schellekens, K. H.; Megens, A. A.; Meert, T. F. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 1988, 244, 685-693.
54. Gray, R. Quetiapine: a new atypical antipsychotic for the treatment of schizophrenia. Ment. Health Care 1998, 1, 163-164.
55. Fuller, R. W.; Snoddy, H. D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res. Commun. Chem. Pathol. Pharmacol. 1992, 77, 87-93.
56. Lowe, J.; Seeger, T.; Nagel, A.; Howard, H.; Seymour, P.; Heym, J.; Ewing, F.; Newman, M.; Schmidt, A. 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1991, 34, 1860-1866.
57. Howard, H.; Lowe, J.; Seeger, T.; Seymour, P.; Zorn, S.; Maloney, P.; Ewing, F.; Newman, M.; Schmidt, A.; Furman, J.; Robinson, G.; Jackson, E.; Johnson, C.; Morrone J. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1996, 39, 143-148.
58. 4 receptor antagonists. Part 1: Identification and structure-activity relationships. Bioorg. Med. Chem. Lett. 2002, 12, 3105-3109.
59. 4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 2002, 12, 3111-3115.
60. Eiser, N. Histamine antagonists and asthma. Pharmacol. Ther. 1982, 17, 239-250.
61. Roquet, A.; Dahlen, B.; Kumlin, M.; Ihre, E.; Gudrun, A.; S. Binks, S. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am. J. Respir. Crit. Care Med. 1997, 155, 1856.
62. 4-receptors. Eur. J. Med. Chem. 1997, 32, 95-102.
63. Lewis, T.; Bayless, L.; Eckman, J.; Ellis, J.; Grewal, G.; Libertine, L.; Nicolas, J.; Scannell, R.; Wels, B.; Wenberg, K.; Wypij, D. 5-Lipoxygenase inhibitors with histamine H1 receptor antagonist activity. Bioorg. Med. Chem. Lett. 2004, 14, 2265-2268.
64. 1 dual antagonizing activity. 1. J. Med. Chem. 1993, 36, 417-420.
65. 1 antagonist chlorpheniramine. Bioorg. Med. Chem. Lett. 2003, 13, 1959-1961.
66. Piwinski, J.; Wong, J.; Green, M.; Ganguly, A.; Billah, M.; West, R.; Kreutner, W. Dual antagonists of platelet-activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene) piperidines. J. Med. Chem. 1991, 34, 457-461.
67. Carceller, E.; Merlos, M.; Giral, M.; Balsa, D.; Almansa, C.; Bartroli, J.; Garcia-Rafanell, J.; Forn, J. [(3-Pyridylalkyl)-piperidylidene] benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine. J. Med. Chem. 1994, 37, 2697-2703.
68. Maynard, G.; Bratton, L.; Kane, J.; Burkholder, T.; Santiago, B.; Stewart, K.; Kudlacz, E.; Shatzer, S.; Knippenberg, R.; Farrell, A.; Logan, D. Synthesis and SAR of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity. Bioorg. Med. Chem. Lett. 1997, 7, 2819-2824.
69. Robl, J.; Sieber-McMaster, E.; Asaad, M. M.; Bird, J. E.; Delaney, N. G.; Barrish, J. C.; Neubeck, R.; Natarajan, S.; Cohen, M.; Rovnyak, G. C.; Huber, G.; Murugesan, N.; Girotra, R.; Cheung, H. S.; Waldron, T.; Petrillo, E. W. Mercaptoacyl dipeptides as dual inhibitors of angiotensin converting enzyme and neutral peptidase. Preliminary structure-activity studies. Bioorg. Med. Chem. Lett. 1994, 4, 1783-1789.
70. Robl, J. A.; Sun, C.-Q.; Stevenson, J.; Ryono, D. E.; Simpkins, L. M.; Cimarusti, M. P.; Dejneka, T.; Slusarchuk, W. A.; Chao, S.; Stratton, L.; Misra, R. N.; Bednarz, M. S.; Asaad, M. M.; Cheung, H. S.; Abboa-Offei, B. E.; Smith, P. L.; Mathers, P. D.; Fox, M.; Schaeffer, T. R.; Seymour, A. A.; Trippodo, N. C. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1997, 40, 1570-1577.
71. Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hake, P. W.; Dage, R. C. Application of conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensinI converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2430.
72. Inguimbert, N.; Poras, H.; Meudal, H.; Teffo, F.; Beslot, F.; Selkti, M.; Tomas, A.; Scalbert, E.; Bennejean, C.; Renard, P.; Fournie-Zaluski, M.-C.; Roques, B. P. N-[2-(Indan-1-yl)-3-mercaptopropionyl] amino acids as highly potent inhibitors of the three vasopeptidase (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg. Med. Chem. Lett. 2002, 12, 2001-2005.
73. Laszlo, S.; Quagliato, C.; Greenlee, W.; Patchett, A.; Chang, R.; Lotti, V.; Chen, T.; Scheck, S.; Faust, K. A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J. Med. Chem. 1993, 36, 3207-3210.
74. Gardiner, S. M.; March, J. E.; Kemp, P. A.; Mullins, J. J.; Bennett, T. Hemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br. J. Pharmacol. 1995, 116, 2237-2244.
75. Walsh, T.; Fitch, K.; Williams, D.; Murphy, K.; Nolan, N.; Pettibone, D.; Chang, R.; O'Malley, S.; Clineschmidt, B.; Veber, D.; Greenlee, W. Potent dual antagonists of endothelin and angiotensin II receptors derived from α-phenoxyphenylacetic acids (Part III). Bioorg. Med. Chem. Lett. 1995, 5, 1155-1158.
76. Murugesan, N.; Tellew, J.; Gu, Z.; Kunst, B.; Fadnis, L.; Cornelius, L.; Baska, R.; Yang, Y.; Beyer, S.; Monshizadegan, H.; Dickinson, K.; Panchal, B.; Valentine, M.; Chong, S.; Morrison, R.; Carlson, K.; Powell, J.; Moreland, S.; Barrish, J.; Kowala, M.; Macor, J. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J. Med. Chem. 2002, 45, 3829-3835.
77. Murugesan, N.; Gu, Z.; Fadnis, L.; Tellew, J.; Baska, R.; Yang, Y.; Beyer, S.; Monshizadegan, H.; Dickinson, K.; Valentine, M.; Humphreys, W.; Lan, S.; Ewing, W.; Carlson, K.; Kowala, M.; Zahler, R.; Macor, J. Dual angiotensin II and endothelin A receptor antagonists: Synthesis of 2′-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J. Med. Chem. 2005, 48, 171-179.
78. Vane, J. R. Nat. New Biol. 1971, 232-235.
79. Dannhard, G.; Kiefer, W. Cyclooxygenase inhibitors-current status and future prospects. Eur. J. Med. Chem. 2001, 36, 109-126.
80. Fosslien, E. Adverse effects of nonsteroidal antiinflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. 1998, 28, 67-81.
81. Gilroy, D. W.; Tomlinson, A.; Willoughby, D. A. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol. 1998, 355, 211-217.
82. Fiorucci, S.; Meli, R.; Bucci, M.; Cirino, G. Dual inhibitors of COX and 5-LOX. A new avenue in anti-inflammatory therapy. Biochem. Pharmacol. 2001, 62, 1433-1438.
83. De Leval, X.; Julemont, F.; Delarge, J.; Pirotte, B.; Dogne, J. M. New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem. 2002, 9, 941-962.
84. Charlier, C.; Michaux, C. Dual inhibition of COX-2 and 5-LOX as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38, 645-659.
85. Swingle, K. F.; Moore, G. G. I. 2,6-Di-tert-4(2′-thenoyl)phenol-(R- 830): A novel nonsteroidal anti-inflammatory agent with antioxidant properties. Agents Actions 1982, 12, 674-683.
86. Lazer, E. S.; Wong, H.-C.; Possanza, G. J.; Graham, A. G.; Farina, P. R. Anti-inflammatory 2,6-di-tert-butyl-4(2-arylethenyl)phenols. J. Med. Chem. 1989, 32, 100-104.
87. Unangst, P. C.; Connor, D. T.; Cetenko, W. A.; Sorenson, R. J.; Kostlan, C. R.; Sircar, J. C.; Wright, C. D.; Schrier, D. J.; Dyer, R. D. Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethyl)-4-hydroxyphenyl]methylene] oxazoles, -thiazoles, and -imidazoles: Novel dual 5-LOX and COX inhibitors with anti-inflamatory activity. J. Med. Chem. 1994, 37, 322-328.
88. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Henichart, J. P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 779-782.
89. Corey, E. J.; Cashman, J. R.; Kantner, S. S.; Wright, S. W. J. Am. Chem. Soc. 1984, 106, 1503.
90. Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. 5-LOX inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 1991, 256, 929-937.
91. Brooks, C. D. W.; Stewart, A. O.; Basha, A.; Bhatia, P.; Ratajczyk, J. D.; Martin, J. G.; Craig, R. A.; Kolasa, T.; Bouska, J. B.; Lanni, C.; Harris, R. R.; Malo, P. E.; Carter, G. W.; Bell, R. L. J. Med. Chem. 1995, 38, 4768.
92. Laufer, S. A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6,7-Diarylhydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem. 1994, 37, 1894-1897.
93. Hibi, S.; Okamoto, Y.; Tagami, K.; Numata, H.; Kobayashi, N.; Shinoda, M.; Kawahara, T.; Murakami, M.; Oketani, K.; Inoue, T.; Shibata, H.; Yamatsu, I. Novel dual inhibitors of 5-LOX and TxA2S: Synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives. J. Med. Chem. 1994, 37, 3062-3070.
94. Fitzgerald, G. A.; Reilly, I. A. G.; Pederson, A. K. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985, 72, 1194-1201.
95. Gresele, P.; van Houte, E.; Arnout, J.; Deckmyn, H.; Vermylen, J. Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy? Thromb. Haemostasis 1984, 52, 364.
96. De Clerck, F.; Beetens, J.; Van de Water, A.; Vercammen, E.; Janssen, P. A. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. II. Pharmacological effects in vivo and ex vivo. Thromb. Haemostasis 1989, 61, 43-49.
97. Kato, K.; Ohkawa, S.; Terao, S.; Terashita, Z. I.; Nishikava, K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of ω-pyridylalkenoic acids. J. Med. Chem. 1985, 28, 287-294.
98. Soyka, R.; Heckel, A.; Nickl, J.; Eisert, W.; Muller, T. H.; Weisenberger, H. 6,6-Disubstituted hex-5-enoic acid derivatives as combined thromboxane A2 receptor and synthetase inhibitors. J. Med. Chem. 1994, 37, 26-39.
99. Dickinson, R. P.; Dack, K. N.; Steele, J. Tromboxane modulating agents. 1. Design of 1-[(arylsulfonyl)amino] alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonist. Bioorg. Med. Chem. Lett. 1995, 5, 3017-3022.
100. Henke, B. Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 2004, 47, 4118-4127.
101. Nomua, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-Substituted benzyl)-thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg. Med. Chem. Lett. 1999, 9, 533-538.
102. Oliver, W. R.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Kelli, D.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliewer, S. A.; Hansen, B. C.; Willson, T. M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5306-5311.
103. Mogensen, J. P.; Jeppesen, L.; Bury, P. S. Design and synthesis of novel PPARα/γ/δ triple activators using known PPARα/γ dual activator as structural template. Bioorg. Med. Chem. Lett. 2003, 13, 257-260.
104. Xu, Y.; Rito, C. J.; Etgen, G. J.; Ardecky, R. J.; Bean, S. J.; Bensch, W. R.; Bosley, J. R.; Broderick, C. L.; Brooks, D. A.; Dominianni, S. J.; Hahn, P. J.; Dale, S. L.; Mais, D. E.; Montrose-Rafizadeh, C.; Ogilvie, K. M.; Oldham, B. A.; Peters, M.; Rungta, D. K.; Shuker, A. J.; Stephenson, G. A.; Tripp, A. E.; Wilson, S. B.; Winneroski, L. L.; Zink, R.; Kauffman, R. K.; McCarthy, J. R. Design and synthesis of α-aryloxy-α-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor α/γ agonists. J. Med. Chem. 2004, 47, 2422-2425.
105. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
106. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
107. Mah, R.; Gerspacher, M.; von Sprecher, A.; Stutzb, S.; Tschinke, V.; Anderson, G.; Bertrand, C.; Subramanian, N.; Ball, H. Biphenyl derivatives as novel dual NK1/NK2-receptor antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 2065-2068.
108. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2003, 46, 550-557.